Cartesian Therapeutics Inc (RNAC)
16.96
-0.66
(-3.75%)
USD |
NASDAQ |
Jul 05, 16:00
16.96
0.00 (0.00%)
After-Hours: 17:13
Cartesian Therapeutics Cash from Financing (Quarterly): 43.03M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 43.03M |
| December 31, 2023 | 14.08M |
| September 30, 2023 | -24.79M |
| June 30, 2023 | -2.586M |
| March 31, 2023 | 0.149M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.612M |
| June 30, 2022 | 36.88M |
| March 31, 2022 | 1.728M |
| December 31, 2021 | 21.16M |
| September 30, 2021 | 1.45M |
| June 30, 2021 | 8.984M |
| March 31, 2021 | 21.31M |
| December 31, 2020 | -0.19M |
| September 30, 2020 | 20.95M |
| June 30, 2020 | -0.957M |
| March 31, 2020 | -5.37M |
| December 31, 2019 | 68.53M |
| September 30, 2019 | 5.028M |
| Date | Value |
|---|---|
| June 30, 2019 | 0.372M |
| March 31, 2019 | 31.11M |
| December 31, 2018 | 0.08M |
| September 30, 2018 | 0.255M |
| June 30, 2018 | 0.311M |
| March 31, 2018 | 0.051M |
| December 31, 2017 | 5.038M |
| September 30, 2017 | 7.331M |
| June 30, 2017 | 53.95M |
| March 31, 2017 | -0.292M |
| December 31, 2016 | 2.792M |
| September 30, 2016 | 2.359M |
| June 30, 2016 | 64.18M |
| March 31, 2016 | -1.677M |
| December 31, 2015 | 5.686M |
| September 30, 2015 | 31.98M |
| June 30, 2015 | 6.442M |
| March 31, 2015 | -0.207M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-24.79M
Minimum
Sep 2023
68.53M
Maximum
Dec 2019
11.05M
Average
1.728M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Marinus Pharmaceuticals Inc | 0.257M |
| Adial Pharmaceuticals Inc | 3.824M |
| Poseida Therapeutics Inc | -0.043M |
| Viracta Therapeutics Inc | -6.598M |
| Biomea Fusion Inc | 0.116M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.92M |
| Cash from Investing (Quarterly) | -0.602M |
| Free Cash Flow | -58.99M |
| Free Cash Flow Per Share (Quarterly) | -3.051 |
| Free Cash Flow to Equity (Quarterly) | -16.52M |
| Free Cash Flow Yield | -66.31% |